Craft

Sunshine Biopharma

Stock Price

$2.9

2024-10-29

Market Capitalization

$5.8 M

2024-10-29

Revenue

$36.3 M

FY, 2025

Sunshine Biopharma Summary

Company Summary

Overview
Sunshine Biopharma is operating as a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer. The Company intends to become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.
Type
Public
Status
Active
Founded
2006
HQ
Pointe-Claire, CA | view all locations
Website
https://sunshinebiopharma.com/
Cybersecurity rating
Sectors

Key People

  • Abderrazzak Merzouki

    Abderrazzak Merzouki, Director, COO

  • David Natan, Director

    LocationsView all

    1 location detected

    • Pointe-Claire, QC HQ

      Canada

      6500 Route Transcanadienne 4th Floor

    Sunshine Biopharma Financials

    Summary Financials

    Revenue (Q1, 2026)
    $8.1M
    Gross profit (Q1, 2026)
    $2.2M
    Net income (Q1, 2026)
    ($1.2M)
    Cash (Q1, 2026)
    $6.9M
    EBIT (Q1, 2026)
    ($1.4M)
    Enterprise value
    ($389.2K)

    Footer menu